The Finn Sawyer Access to Cancer Testing Act aims to enhance access to advanced cancer diagnostics and facilitate the development of cancer treatments. It significantly expands Medicare coverage to include specific cancer diagnostic and laboratory tests , such as microarray analysis, DNA sequencing, RNA sequencing, and whole-exome sequencing, along with their interpretation. These tests are covered for individuals diagnosed with cancer, with specific frequencies for diagnosis, recurrence, and treatment planning or monitoring. Under Medicare, payment for these tests will be 80% (or 100% for assignment-related claims) of the lesser of the actual charge or a determined amount, and importantly, the standard Medicare deductible will not apply. The bill also mandates the inclusion of these cancer diagnostic and laboratory tests as "medical assistance" under Medicaid , making their coverage mandatory for states, with an effective date of January 1, 2027. Furthermore, CHIP is required to cover these tests for targeted low-income children and pregnant women starting January 1, 2025, regardless of the state's chosen coverage type. Beyond coverage expansion, the Act establishes an important education and awareness program . This program, to be carried out by the Secretary of Health and Human Services in coordination with the National Human Genome Research Institute, will inform physicians and the general public about genomic testing, its applications, and the role of genetic counselors. It specifically encourages the integration of education and training on molecular diagnostics for cancer into graduate and continuing medical education, particularly for oncology specialists, to detect mutations at diagnosis and recurrence.